Table 3.
Interaction between EMT-related genes and Chemicals by Comparative Toxicogenomics Database (CTD).
| Gene | Disease | Chemicals (Antineoplastic Drugs)—Inference Network | Inference Score |
|---|---|---|---|
| MMP2 | Neoplasm Invasiveness | Capecitabine, Celecoxib, Doxorubicin, Tamoxifen, Sorafenib | 420.88 |
| Neoplasm Metastasis | Capecitabine, Celecoxib, Cisplatin, Doxorubicin, Oxaliplatin, Paclitaxel, Sorafenib, Sunitinib, Tamoxifen | 236.27 | |
| Glioblastoma | Cisplatin, Doxorubicin, Paclitaxel | 77.57 | |
| MAP1B | Cell Transformation, Neoplastic | Daunorubicin, Doxorubicin | 99.91 |
| Lung Neoplasms | Doxorubicin | 65.01 | |
| Glioblastoma | Doxorubicin, Fenretinide | 39.53 | |
| SNAI2 | Neoplasm Invasiveness | Fulvestrant, Doxorubicin, Gefitinib, Palbociclib, Sorafenib | 166.23 |
| Lung Neoplasms | Cisplatin, Decitabine, Doxorubicin, Erlotinib Hydrochloride, Gefitinib | 155.86 | |
| Nerve Degeneration | Cisplatin, Cytarabine, Doxorubin, Fulvestrant | 127.01 | |
| WNT5A | Lung Neoplasms | Azacitidine, Cisplatin, Decitabine, Doxorubicin, Gemcitabine, Tamoxifen | 138.80 |
| Cell Transformation, Neoplastic | Cisplatin, Decitabine, Doxorubicin | 125.01 | |
| Cognition Disorders | Cisplatin, Diazinon, Doxorubicin, Gemcitabine, Genistein, Methotrexate, Tamoxifen | 139.07 |